BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed NVS catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:be3c6f1e8801496601f9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:NVS P2 readout (est.): An Open-label Study of JSB462 (Luxdegalutami
 de) in Combination With Abiraterone in Adult Male Patients With Metastatic
  Hormone-sensitive Prostate Cancer (mHSPC)
DESCRIPTION:An Open-label Study of JSB462 (Luxdegalutamide) in Combination 
 With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive 
 Prostate Cancer (mHSPC)\nNCT06991556 | PHASE2 | ACTIVE_NOT_RECRUITING | sp
 onsor: Novartis Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nTicker NVS (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT06991556\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06991556
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e83e71bc9fa3edef1880@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:NVS P2 readout (est.): PSMACare
DESCRIPTION:A Phase II Study of AAA617 Alone and AAA617 in Combination With
  ARPI in Patients With PSMA PET Scan Positive CRPC\nNCT05849298 | PHASE2 |
  ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nTicker NVS
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05849298\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05849298
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3e04c77b7d0e58aee62c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:NVS P2 readout (est.): Iptacopan in Patients With ANCA Associated V
 asculitis
DESCRIPTION:Iptacopan in Patients With ANCA Associated Vasculitis\nNCT06388
 941 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals\n
 Primary completion date (ESTIMATED)\; top-line results usually follow late
 r.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltrials.gov/study/
 NCT06388941\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06388941
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c2e8e1b3ae4824e4cc1e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:NVS P3 readout (est.): ACS
DESCRIPTION:Evaluation of Efficacy and Safety of Early in Hospital Initiati
 on of Inclisiran Treatment in Patients With Acute Coronary Syndromes\nNCT0
 7102628 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceutica
 ls\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltrials.gov/st
 udy/NCT07102628\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07102628
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:13d3b904d9cc35d67d05@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:NVS P1/P2 readout (est.): KontRASt-01
DESCRIPTION:Study of JDQ443 in Patients With Advanced Solid Tumors Harborin
 g the KRAS G12C Mutation\nNCT04699188 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUIT
 ING | sponsor: Novartis Pharmaceuticals\nPrimary completion date (ESTIMATE
 D)\; top-line results usually follow later.\nTicker NVS (confidence 0.9)\n
 Source: https://clinicaltrials.gov/study/NCT04699188\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04699188
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2a041b7fae76a9fed45b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:NVS P3 readout (est.): EPIK-B5
DESCRIPTION:Study to Assess the Efficacy and Safety of Alpelisib Plus Fulve
 strant in Participants With HR-positive (HR+)\, HER2-negative\, Advanced B
 reast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhi
 bitor.\nNCT05038735 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Novartis P
 harmaceuticals\nPrimary completion date (ESTIMATED)\; top-line results usu
 ally follow later.\nTicker NVS (confidence 0.9)\nSource: https://clinicalt
 rials.gov/study/NCT05038735\nScheduling/reference data from public records
 \; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05038735
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:82cb970664b184f7a02c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:NVS P2 readout (est.): Study Assessing the Efficacy and Safety of T
 reatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant i
 n Chinese Men and Postmenopausal Women With Advanced Breast Cancer
DESCRIPTION:Study Assessing the Efficacy and Safety of Treatment With Alpel
 isib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and P
 ostmenopausal Women With Advanced Breast Cancer\nNCT04544189 | PHASE2 | AC
 TIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nTicker NVS (c
 onfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT04544189\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04544189
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3c2ad869b7b783542030@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:NVS P3 readout (est.): APPEAR-C3G
DESCRIPTION:Study of Efficacy and Safety of Iptacopan in Patients With C3 G
 lomerulopathy.\nNCT04817618 | PHASE3 | RECRUITING | sponsor: Novartis Phar
 maceuticals\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltria
 ls.gov/study/NCT04817618\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04817618
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:195c04d7bb3273ef73d6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:NVS P2 readout (est.): Ribociclib (LEE011) Rollover Study for Conti
 nued Access
DESCRIPTION:Ribociclib (LEE011) Rollover Study for Continued Access\nNCT029
 34568 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT02934568\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02934568
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:989f6de5256b93567a8a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:NVS P2 readout (est.): Study of Efficacy and Safety of LXH254 Combi
 nations in Patients With Previously Treated Unresectable or Metastatic Mel
 anoma
DESCRIPTION:Study of Efficacy and Safety of LXH254 Combinations in Patients
  With Previously Treated Unresectable or Metastatic Melanoma\nNCT04417621 
 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Novartis Pharmaceuticals\nPrim
 ary completion date (ESTIMATED)\; top-line results usually follow later.\n
 Ticker NVS (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 4417621\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04417621
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f5f01c73af6a21e0d09d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:NVS P2 readout (est.): PLATINUM
DESCRIPTION:Platform Study to Evaluate the Efficacy and Safety of Anti-mala
 rial Agents in Participants With Uncomplicated Plasmodium Falciparum Malar
 ia (Cohort C2)\nNCT07811908 | PHASE2 | RECRUITING | sponsor: Novartis Phar
 maceuticals\nPrimary completion date (ESTIMATED)\; top-line results usuall
 y follow later.\nTicker NVS (confidence 0.9)\nSource: https://clinicaltria
 ls.gov/study/NCT07811908\nScheduling/reference data from public records\; 
 dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07811908
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3e87805a3a2875d73c03@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261015
DTEND;VALUE=DATE:20261016
SUMMARY:NVS APPROVAL: COSENTYX
DESCRIPTION:Approved 2026-10-15: COSENTYX (BLA761349 SUPPL13)\nConfidence: 
 confirmed\nTicker NVS (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761349\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761349
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:66f1a2c70cb2f4646965@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261006
DTEND;VALUE=DATE:20261007
SUMMARY:NVS APPROVAL: RHAPSIDO
DESCRIPTION:Approved 2026-10-06: RHAPSIDO (NDA218436 SUPPL1)\nConfidence: c
 onfirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218436\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218436
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:3ae8ed265960024bbafe@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260731
DTEND;VALUE=DATE:20260801
SUMMARY:NVS APPROVAL: PLUVICTO
DESCRIPTION:Approved 2026-07-31: PLUVICTO (NDA215833 SUPPL37)\nConfidence: 
 confirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215833\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215833
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2167a59f8251e5bfb139@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260716
DTEND;VALUE=DATE:20260717
SUMMARY:NVS APPROVAL: FABHALTA
DESCRIPTION:Approved 2026-07-16: FABHALTA (NDA218276 SUPPL7)\nConfidence: c
 onfirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218276\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218276
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:5c64100dcbf95854296b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260701
DTEND;VALUE=DATE:20260702
SUMMARY:NVS APPROVAL: KISQALI FEMARA CO-PACK (COPACKAGED)
DESCRIPTION:Approved 2026-07-01: KISQALI FEMARA CO-PACK (COPACKAGED) (NDA20
 9935 SUPPL33)\nConfidence: confirmed\nTicker NVS (confidence 0.9)\nSource:
  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.
 process&ApplNo=209935\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=209935
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:db040a8bf9aed5580703@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260701
DTEND;VALUE=DATE:20260702
SUMMARY:NVS APPROVAL: KISQALI
DESCRIPTION:Approved 2026-07-01: KISQALI (NDA209092 SUPPL27)\nConfidence: c
 onfirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=209092
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:39b62ca53c423eedc6d7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260417
DTEND;VALUE=DATE:20260418
SUMMARY:NVS APPROVAL: COSENTYX
DESCRIPTION:Approved 2026-04-17: COSENTYX (BLA125504 SUPPL97)\nConfidence: 
 confirmed\nTicker NVS (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125504
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b4f6104860db361afb3c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260417
DTEND;VALUE=DATE:20260418
SUMMARY:NVS APPROVAL: COSENTYX
DESCRIPTION:Approved 2026-04-17: COSENTYX (BLA125504 SUPPL98)\nConfidence: 
 confirmed\nTicker NVS (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125504
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:852987181c358d561e39@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260312
DTEND;VALUE=DATE:20260313
SUMMARY:NVS APPROVAL: COSENTYX
DESCRIPTION:Approved 2026-03-12: COSENTYX (BLA125504 SUPPL91)\nConfidence: 
 confirmed\nTicker NVS (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125504\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125504
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c7190944ad667cea883d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260212
DTEND;VALUE=DATE:20260213
SUMMARY:NVS APPROVAL: LEQVIO
DESCRIPTION:Approved 2026-02-12: LEQVIO (NDA214012 SUPPL18)\nConfidence: co
 nfirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214012\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=214012
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c6d9822a3b1baa8a9c16@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260212
DTEND;VALUE=DATE:20260213
SUMMARY:NVS APPROVAL: LEQVIO
DESCRIPTION:Approved 2026-02-12: LEQVIO (NDA214012 SUPPL17)\nConfidence: co
 nfirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214012\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=214012
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c5404e6f1ff0cf9482e0@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251125
DTEND;VALUE=DATE:20251126
SUMMARY:NVS APPROVAL: SCEMBLIX
DESCRIPTION:Approved 2025-11-25: SCEMBLIX (NDA215358 SUPPL12)\nConfidence: 
 confirmed\nTicker NVS (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215358
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
